160 related articles for article (PubMed ID: 38861054)
1. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
Khene ZE; Lotan Y
Expert Opin Biol Ther; 2024 Jun; 24(6):415-423. PubMed ID: 38861054
[TBL] [Abstract][Full Text] [Related]
2. Nadofaragene Firadenovec: First Approval.
Lee A
Drugs; 2023 Mar; 83(4):353-357. PubMed ID: 36856952
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.
Joshi M; Atlas SJ; Beinfeld M; Chapman RH; Rind DM; Pearson SD; Touchette DR
Value Health; 2023 Jun; 26(6):823-832. PubMed ID: 36529422
[TBL] [Abstract][Full Text] [Related]
4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Sawutz D; Philipson R; Coll R; Narayan VM; Treasure FP; Yla-Herttuala S; Parker NR; Dinney CPN
Lancet Oncol; 2021 Jan; 22(1):107-117. PubMed ID: 33253641
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Narayan VM; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Inman BA; Williams MB; Cookson MS; Chang SS; Sankin AI; O'Donnell MA; Sawutz D; Philipson R; Parker NR; Yla-Herttuala S; Rehm D; Jakobsen JS; Juul K; Dinney CPN
J Urol; 2024 Jul; 212(1):74-86. PubMed ID: 38704840
[TBL] [Abstract][Full Text] [Related]
7. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
Mitra AP; Narayan VM; Mokkapati S; Miest T; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown GA; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Philipson R; Ylä-Herttuala S; Sawutz D; Parker NR; McConkey DJ; Dinney CPN
Eur Urol; 2022 Mar; 81(3):223-228. PubMed ID: 34933753
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Kokorovic A; Ory J; Saad F
Curr Opin Support Palliat Care; 2022 Mar; 16(1):48-53. PubMed ID: 35086977
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of nadofaragene firadenovec-vncg.
Narayan VM; Meeks JJ; Jakobsen JS; Shore ND; Sant GR; Konety BR
Front Oncol; 2024; 14():1359725. PubMed ID: 38559556
[TBL] [Abstract][Full Text] [Related]
10. Emerging treatment landscape of non-muscle invasive bladder cancer.
Valenza C; Antonarelli G; Giugliano F; Aurilio G; Verri E; Briganti A; Curigliano G; Necchi A
Expert Opin Biol Ther; 2022 Jun; 22(6):717-734. PubMed ID: 35634893
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
[TBL] [Abstract][Full Text] [Related]
13. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
Nykopp TK; Batista da Costa J; Mannas M; Black PC
Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
[TBL] [Abstract][Full Text] [Related]
14. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
16. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
17. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
[TBL] [Abstract][Full Text] [Related]
18. [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer].
Leucht K; Foller S; Grimm MO
Urologe A; 2021 Nov; 60(11):1400-1408. PubMed ID: 34709440
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial.
Achard V; Fournier B; D'Haese D; Krzystyniak J; Tombal B; Roupret M; Sargos P; Dirix P
Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38556413
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]